Qureight showcases the power of AI-driven image analytics across eight presentations at the 2025 ATS International Conference
How is deep learning imaging advancing drug discovery for fibrosis?
Drug Discovery World
Appointment of Dr. Paul Ford MD, PhD as Senior Clinical Development Advisor
Qureight Board of Directors elects Dr. Neil Johnston to the Board as Non-Executive Chair
The role of NHS Big Data and AI technology in unlocking the future of lung and heart disease treatment
pharmaphorum
Qureight and Remedy Cell to validate RC-0315 in Phase Ib trial for IPF
Clinical Trials Arena
Qureight and Remedy Cell partner to integrate deep learning platform into Phase 1b study of RC-0315 in IPF
Qureight Appoints Patrick Driscoll as Chief Financial Officer
Starting 2025 on a high!
Vicore Pharma to track lung fibrosis trial with Qureight's AI-powered imaging platform
FirstWord PHARMA
Qureight core imaging platform deployed within Vicore Phase 2b ASPIRE study of buloxibutid for IPF
Qureight tech deployed in lung fibrosis clinical trial
Health Tech World
Qureight and Avalyn Launch Strategic Partnership in Progressive Pulmonary Fibrosis
Pharma Focus Europe
Qureight and Avalyn launch strategic partnership in pulmonary fibrosis
PharmaTimes Online
Qureight achieves ISO 27001 certification: gold standard for data security in healthcare
Unravelling the most complex disease challenges in history: How AI startups are changing drug discovery
Startups Magazine
An Autumn Team Update From Qureight
